Eukaryotic translation initiation factor 4A1 (EIF4A1) and Eukaryotic translation initiation factor 4A2 (EIF4A2) (eIF4A1 and eIF4A2)

Eukaryotic translation initiation factor 4A1 (eIF4A1) and 4A2 (eIF4A2) are closely related DEAD-box RNA helicases that are core components of the eukaryotic translation initiation complex. Their primary role is to unwind secondary structures in the 5′ untranslated region (UTR) of mRNAs, using ATP hydrolysis, to facilitate ribosome scanning and efficient translation initiation. Both eIF4A1 and eIF4A2 are required for proper binding of mRNA to the 40S ribosomal subunit; they function within the multi-subunit eIF4F complex (alongside eIF4E and eIF4G) and are fundamental to protein synthesis in eukaryotic cells[1][2][3][7]. eIF4A1 is particularly associated with oncogenicity and has been implicated in the growth and survival of cancer cells, making it a focus of current drug discovery targeting translation control mechanisms[2][3]. Selective inhibitors, including natural compounds like rocaglamide and hippuristanol, have shown potential in preclinical models. Due to their critical roles in global protein synthesis, targeting eIF4A1/2 carries significant therapeutic promise but also raises challenges regarding selectivity and toxicity.

Other names

eIF4A1eIF4A2Eukaryotic initiation factor 4A-IEukaryotic initiation factor 4A-II

Inhibition of ATP-dependent RNA helicase activity blocks mRNA unwinding, thereby impeding translation initiation[1][2].